William E Klunk1, Chester A Mathis. 1. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. klunkwe@upmc.edu
Abstract
PURPOSE OF REVIEW: This review will focus on the coming proliferation of amyloid-beta imaging tracers and give an opinion on how the Alzheimer's disease field can develop a systematic means of evaluating which tracers are useful and how the useful tracers compare to each other. RECENT FINDINGS: Several new tracers have been reported to be useful for human amyloid-beta imaging. The most recent of these are labeled with fluorine-18. Compared with the 20 min half-life of carbon-11 used in the most widely used tracer, Pittsburgh Compound-B, the 110 min half-life of fluorine-18 allows for wider utilization in research and clinical settings. SUMMARY: It is likely that more than one fluorine-18-labeled tracer will come into common use. The use of preclinical and clinical 'bridging studies' to [C-11]Pittsburgh Compound-B could be a means to determine whether the sizable body of knowledge already gained in [C-11]Pittsburgh Compound-B studies can be applied to the understanding of these new tracers and to form a basis for the comparison among them. This approach could save resources and help sort out a potentially bewildering onslaught of new amyloid-beta imaging tracers.
PURPOSE OF REVIEW: This review will focus on the coming proliferation of amyloid-beta imaging tracers and give an opinion on how the Alzheimer's disease field can develop a systematic means of evaluating which tracers are useful and how the useful tracers compare to each other. RECENT FINDINGS: Several new tracers have been reported to be useful for humanamyloid-beta imaging. The most recent of these are labeled with fluorine-18. Compared with the 20 min half-life of carbon-11 used in the most widely used tracer, Pittsburgh Compound-B, the 110 min half-life of fluorine-18 allows for wider utilization in research and clinical settings. SUMMARY: It is likely that more than one fluorine-18-labeled tracer will come into common use. The use of preclinical and clinical 'bridging studies' to [C-11]Pittsburgh Compound-B could be a means to determine whether the sizable body of knowledge already gained in [C-11]Pittsburgh Compound-B studies can be applied to the understanding of these new tracers and to form a basis for the comparison among them. This approach could save resources and help sort out a potentially bewildering onslaught of new amyloid-beta imaging tracers.
Authors: Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio Journal: N Engl J Med Date: 2006-12-21 Impact factor: 91.245
Authors: Keith A Johnson; Matt Gregas; John A Becker; Catherine Kinnecom; David H Salat; Erin K Moran; Erin E Smith; Jonathan Rosand; Dorene M Rentz; William E Klunk; Chester A Mathis; Julie C Price; Steven T Dekosky; Alan J Fischman; Steven M Greenberg Journal: Ann Neurol Date: 2007-09 Impact factor: 10.422
Authors: Kerryn E Pike; Greg Savage; Victor L Villemagne; Steven Ng; Simon A Moss; Paul Maruff; Chester A Mathis; William E Klunk; Colin L Masters; Christopher C Rowe Journal: Brain Date: 2007-10-10 Impact factor: 13.501
Authors: William E Klunk; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Brian J Lopresti; Scott K Ziolko; Wenzhu Bi; Jessica A Hoge; Ann D Cohen; Milos D Ikonomovic; Judith A Saxton; Beth E Snitz; Daniel A Pollen; Majaz Moonis; Carol F Lippa; Joan M Swearer; Keith A Johnson; Dorene M Rentz; Alan J Fischman; Howard J Aizenstein; Steven T DeKosky Journal: J Neurosci Date: 2007-06-06 Impact factor: 6.167
Authors: G D Rabinovici; A J Furst; J P O'Neil; C A Racine; E C Mormino; S L Baker; S Chetty; P Patel; T A Pagliaro; W E Klunk; C A Mathis; H J Rosen; B L Miller; W J Jagust Journal: Neurology Date: 2007-04-10 Impact factor: 9.910
Authors: C C Rowe; S Ng; U Ackermann; S J Gong; K Pike; G Savage; T F Cowie; K L Dickinson; P Maruff; D Darby; C Smith; M Woodward; J Merory; H Tochon-Danguy; G O'Keefe; W E Klunk; C A Mathis; J C Price; C L Masters; V L Villemagne Journal: Neurology Date: 2007-05-15 Impact factor: 9.910
Authors: A L Boxer; G D Rabinovici; V Kepe; J Goldman; A J Furst; S-C Huang; S L Baker; J P O'neil; H Chui; M D Geschwind; G W Small; J R Barrio; W Jagust; B L Miller Journal: Neurology Date: 2007-07-17 Impact factor: 9.910
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2011-11-02 Impact factor: 21.566
Authors: Steven E Arnold; Edward B Lee; Paul J Moberg; Lauren Stutzbach; Hala Kazi; Li-Ying Han; Virginia M Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2010-04 Impact factor: 10.422
Authors: Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung Journal: J Nucl Med Date: 2009-10-16 Impact factor: 10.057
Authors: André F Martins; Alexandre C Oliveira; Jean-François Morfin; Douglas V Laurents; Éva Tóth; Carlos F G C Geraldes Journal: J Biol Inorg Chem Date: 2015-11-27 Impact factor: 3.358